Investors

Corporate Profile
We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.
Stock Quote
ERYP.PA (Common Stock)
ExchangeParis (Euro)
Price€14.77
Change (%) Stock is Down 0.06 (0.40%)
Volume19,018
Data as of 03/01/17 5:35 p.m. ET
Refresh quote
Recent NewsMore >>
DateTitle  
28-Feb-2017ERYTECH to Hold Business Update and 2016 Financial Results Conference Call on March 3rd, 2017
LYON, France--(BUSINESS WIRE)--Feb. 28, 2017-- Regulatory News: ERYTECH (Paris:ERYP) (ADR:EYRYY) :, the clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced that it will release its financial results and business update for the year ended December 31, 2... 
 Printer Friendly Version
17-Jan-2017ERYTECH Presents New Preclinical Data on ERY-MET at the 2017 ASCO GI Symposium
LYON, France--(BUSINESS WIRE)--Jan. 17, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs (the "Company"), today announced new data supporting the second Company’s product candidate ERY-MET will be presented at the 2017 Gastrointe... 
 Printer Friendly Version
06-Jan-2017Erytech Pharma: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital – December 2016
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Jan. 6, 2017-- Regulatory News: Erytech Pharma (Paris:ERYP) (ADR:EYRYY): Listing market: Euronext Paris from Euronext Market segment : segment B ISIN Code : FR0011471135 website : www.erytech.com Date   ... 
 Printer Friendly Version
06-Dec-2016Erytech Pharma: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital – November 2016
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Dec. 6, 2016-- Regulatory News: Erytech Pharma (Paris:ERYP) (ADR:EYRYY): Listing market: Euronext Paris from Euronext Market segment : segment B ISIN Code : FR0011471135 website : www.erytech.com Date   ... 
 Printer Friendly Version
Upcoming EventsMore >>
DateTitle
03/02/17
Fourth Quarter and Full-Year 2016 Financial Results and Business Update: Press Release: Thursday, March 2, 2017 (after market)
03/03/17 3:00 p.m. CET
Fourth Quarter and Full-Year 2016 Financial Results and Business Update: Conference Call
05/18/17
First Quarter 2017 Financial Results and Business Update: Press Release: Thursday, May 18, 2017 (after market)
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Erytech Pharma SA posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
Top